 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...899900901902903904905906907908909...910911» |
- |||| Repatha (evolocumab) / Amgen, Astellas
Trial completion: MENDEL: Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels (clinicaltrials.gov) - Jun 13, 2012
P2, N=411, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Enrollment change: Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy (clinicaltrials.gov) - Jun 12, 2012
P2, N=3, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=11 --> 3
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change, Surgery: The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial (clinicaltrials.gov) - Jun 11, 2012
P2, N=9, Completed, Sponsor: University of Pennsylvania
N=11 --> 3 N=40 --> 9
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
Clinical: Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety. (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=50, Completed, Sponsor: Henri Mondor University Hospital
- Biomarker, Enrollment open: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 11, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
N=40 --> 9 Not yet recruiting --> Recruiting
- prednisone / Generic mfg., mitoxantrone / Generic mfg., cabazitaxel / Generic mfg.
Enrollment open, Metastases: Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 11, 2012
P1, N=42, Recruiting, Sponsor: Eric Small
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Vectibix (panitumumab) / Amgen
Trial completion: Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations (clinicaltrials.gov) - Jun 11, 2012
P2, N=32, Completed, Sponsor: Vejle Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion, Surgery: The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial (clinicaltrials.gov) - Jun 11, 2012
P2, N=9, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Suspended --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma (clinicaltrials.gov) - Jun 10, 2012
P2, N=11, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Suspended --> Completed N=54 --> 11
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1/2 trial: FFAD: Efficacy and Safety of Filgrastim in Alzheimer's Disease (clinicaltrials.gov) - Jun 10, 2012
P1/2, N=8, Completed, Sponsor: University of South Florida
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma (clinicaltrials.gov) - Jun 10, 2012
P2, N=11, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=54 --> 11 Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: CREST: Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients (clinicaltrials.gov) - Jun 6, 2012
P4, N=34, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed N=51 --> 34
- Enrollment closed: Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants (clinicaltrials.gov) - Jun 6, 2012
P2, N=115, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=51 --> 34 Recruiting --> Active, not recruiting
- Clinical: Causes of Visual Loss in Retinal Disease (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=2000, Enrolling by invitation, Sponsor: Royal Surrey County Hospital
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mustargen (mechlorethamine) / Recordati
Enrollment closed: Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma (clinicaltrials.gov) - Jun 5, 2012
P2, N=82, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Trial completion: Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction (clinicaltrials.gov) - Jun 5, 2012
P2, N=69, Completed, Sponsor: American College of Surgeons
Recruiting --> Active, not recruiting Recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P3, N=19, Terminated, Sponsor: Southwest Oncology Group
Recruiting --> Completed Active, not recruiting --> Terminated; poor accrual
- ||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (clinicaltrials.gov) - Jun 4, 2012
P3, N=127, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated; poor accrual N=100 --> 127
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2012
P3, N=19, Terminated, Sponsor: Southwest Oncology Group
N=100 --> 127 N=320 --> 19
- | Traficet-EN (vercirnon) / Amgen
New P1 trial: Japanese Phase I of GSK1605786 (clinicaltrials.gov) - Jun 3, 2012
P1, N=30, Completed, Sponsor: GlaxoSmithKline
- ||||||| Neugranin (balugrastim biosimilar) / Teva
Trial completion, Head-to-Head: NEUGR-003: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (clinicaltrials.gov) - Jun 3, 2012
P3, N=381, Completed, Sponsor: Teva Pharmaceutical Industries
N=320 --> 19 Active, not recruiting --> Completed
- Clinical: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity (clinicaltrials.gov) - May 31, 2012
P=N/A, N=398, Recruiting, Sponsor: University Hospital, Montpellier
- | trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
New P2 trial: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (clinicaltrials.gov) - May 30, 2012
P2, N=141, Recruiting, Sponsor: National Cancer Institute (NCI)
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis (clinicaltrials.gov) - May 28, 2012
P0, N=30, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen, MB-207 / Fortress
Enrollment open: Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - May 25, 2012
P1/2, N=20, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases, St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Suspended --> Recruiting
- | New P4 trial: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - May 22, 2012
P4, N=190, Recruiting, Sponsor: Spanish Clinical Pharmacology Society
- Vectibix (panitumumab) / Amgen
Enrollment change: Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab (clinicaltrials.gov) - May 21, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Suspended --> Recruiting N=40 --> 0
- | Ibrance (palbociclib) / Pfizer
New P1 trial: Relative Bioavailability Study (clinicaltrials.gov) - May 17, 2012
P1, N=24, Completed, Sponsor: Pfizer
- Epogen (epoetin alfa) / Amgen
Trial completion: REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (clinicaltrials.gov) - May 17, 2012
P2, N=250, Completed, Sponsor: National Institute on Aging (NIA)
N=40 --> 0 Active, not recruiting --> Completed
- | Biomarker, New P4 trial: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - May 16, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Enrollment open, Metastases: A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies (clinicaltrials.gov) - May 15, 2012
P1, N=18, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 15, 2012
P3, N=592, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Stivarga (regorafenib) / Bayer
Trial completion, Combination therapy, Metastases: Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI (clinicaltrials.gov) - May 14, 2012
P1, N=45, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
New P1 trial: Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone (clinicaltrials.gov) - May 13, 2012
P1, N=24, Completed, Sponsor: Astellas Pharma Global Development, Inc.
- Rituxan (rituximab) / Roche
Trial completion: SAKK 34/02: Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL (clinicaltrials.gov) - May 13, 2012
P2, N=43, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: SAKK 57/93: Chemotherapy in Treating Patients With Advanced Sarcoma (clinicaltrials.gov) - May 13, 2012
P2, N=20, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (clinicaltrials.gov) - May 10, 2012
P3, N=1225, Active, not recruiting, Sponsor: Eli Lilly and Company
- ||||| Evrenzo (roxadustat) / FibroGen
New P2 trial: Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China (clinicaltrials.gov) - May 9, 2012
P2, N=96, Completed, Sponsor: FibroGen
- Kepivance (palifermin) / SOBI, Amgen
Trial withdrawal: KGF Haplo Allo: Palifermin After Haploidentical PBSCT (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: European Group for Blood and Marrow Transplantation
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: KGF Haplo Allo: Palifermin After Haploidentical PBSCT (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: European Group for Blood and Marrow Transplantation
Not yet recruiting --> Withdrawn N=100 --> 0
- | prednisone / Generic mfg., mitoxantrone / Generic mfg., cabazitaxel / Generic mfg.
New P1 trial, Metastases: Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - May 7, 2012
P1, N=42, Recruiting, Sponsor: Eric Small
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2012
P3, N=315, Recruiting, Sponsor: Children's Oncology Group
N=100 --> 0 N=244 --> 315
- buparlisib (AN2025) / Adlai Nortye, Vectibix (panitumumab) / Amgen
New P1/2 trial: P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (clinicaltrials.gov) - May 2, 2012
P1/2, N=40, Recruiting, Sponsor: NCIC Clinical Trials Group
- Vectibix (panitumumab) / Amgen
New P2 trial: Investigation of efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients with colorectal cancer liver metastasis (EUDRACT) - May 1, 2012
P2, N=36, Ongoing, Sponsor: ABCSG (Austrian Breast & Colorectal Cancer Study Group)
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P2/3 trial: Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (clinicaltrials.gov) - Apr 29, 2012
P2/3, N=58, Completed, Sponsor: Amgen
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: Transition From Alendronate to Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 29, 2012
P1, N=60, Completed, Sponsor: Amgen
- |||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Trial completion: HALT-HE: A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (clinicaltrials.gov) - Apr 29, 2012
P2, N=193, Completed, Sponsor: Hyperion Therapeutics, Inc.
N=244 --> 315 Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
New P2 trial: Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS Estudio de fase II de panitumumab y capecitabina como tratamiento de primera l (EUDRACT) - Apr 25, 2012
P2, N=36, Ongoing, Sponsor: Grupo Gallego de Investigaci
- | Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen
New P1 trial: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 24, 2012
P1, N=28, Recruiting, Sponsor: MedImmune LLC
- |||||||||| Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: CONCUR: Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (clinicaltrials.gov) - Apr 23, 2012
P3, N=204, Active, not recruiting, Sponsor: Bayer